TYK Medicines, Inc. has issued the proxy form for its 2025 Annual General Meeting scheduled for 2:00 p.m. on 23 June 2026 at 8/F, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai.

The meeting will vote on eight ordinary resolutions: 1. Directors’ report for 2025. 2. 2025 annual report. 3. Audited financial statements for 2025. 4. Directors’ remuneration for 2026. 5. Re-appointment of Ernst & Young as external auditor and authorisation for the Board to set its fee. 6. Profit distribution plan for 2025. 7. Re-election of Mr. Jiang Xiaolin as independent non-executive director. 8. Bank credit facility plan for 2026.

Three special resolutions will also be considered: 9. A general mandate authorising the Board to issue shares. 10. A mandate authorising the repurchase of H shares. 11. Amendments to the Articles of Association.

Shareholders wishing to vote by proxy must deposit the signed form with Computershare Hong Kong Investor Services Limited no later than 24 hours before the meeting. Attendance in person is permitted, and identity documents are required for entry.